N-(tert-butoxycarbonyl)cysteine ethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(tert-butoxycarbonyl)cysteine ethyl ester
• 英文别名: Ethyl 2-[(tert-butoxycarbonyl)amino]-3-sulfanylpropanoate；ethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-sulfanylpropanoate
• 化学式: C₁₀H₁₉NO₄S
• 分子量: 249.331
• InChiKey: ZJZLASCAYWETRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  65.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)cysteine ethyl ester 在 magnesium bromide ethyl etherate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 7.5h， 生成
  参考文献：
  名称：

  A Bioinspired Synthesis of 1,4-Benzothiazines by Selective Addition of Sulfur Nucleophiles to ortho-Quinones

  摘要：

  DOI：

  10.1021/acs.joc.2c02463

文献信息

• AGENT FOR PREVENTING OR TREATING PANCREAS CANCER, OVARY CANCER OR LIVER CANCER CONTAINING NOVEL WATER-SOLUBLE PRODRUG
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1938823A1

  公开（公告）日：2008-07-02

  Preventive or therapeutic agents for pancreatic cancer, ovarian cancer, or liver cancer of the present invention comprise a water-soluble prodrug represented by formula 1 described below, or a pharmaceutically acceptable salt, or a hydrate or solvate of the prodrug or pharmaceutically acceptable salt, (wherein, R1 represents a hydrogen atom, or a C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or a divalent group comprising a sulfonyl group, and Y represents a residue of a compound represented by Y-OH comprising an alcoholic hydroxyl group, wherein said Y-OH is a camptothecin, a taxane, or an anticancer nucleotide).

  预防或治疗胰腺癌、卵巢癌或肝癌的本发明药剂包括下述式子所代表的水溶性前药，或者前药的药用可接受盐，或者前药或药用可接受盐的水合物或溶剂化合物， （其中， R1代表氢原子，或者C1-C6烷基； W代表包含三级胺基团或含磺酰基团的二价基团，以及 Y代表由Y-OH所代表的化合物残基，包括含有醇羟基的醇羟基化合物残基，其中所述的Y-OH是一种喜树碱、紫杉醇或抗癌核苷酸）。
• The cytotoxicity of garlic-related disulphides and thiosulfonates in WHCO1 oesophageal cancer cells is dependent on S-thiolation and not production of ROS
  作者：Muneerah Smith、Roger Hunter、Nashia Stellenboom、Daniel A. Kusza、M. Iqbal Parker、Ahmed N.H. Hammouda、Graham Jackson、Catherine H. Kaschula

  DOI：10.1016/j.bbagen.2016.03.032

  日期：2016.7

  mechanism that relies on the thermodynamics of a mixed disulphide exchange reaction. Disulphide (1) and thiosulfonate (11) were further evaluated mechanistically and found to induce G2/M cell-cycle arrest and apoptosis, inhibit cell proliferation, and generate ROS. When the ROS produced by 1 and 11 were quenched with Trolox, ascorbic acid or N-acetyl cysteine (NAC), only NAC was found to counter the cytotoxicity

  背景 大蒜因其促进健康和预防癌症的特性已在民间医学中使用了多个世纪。压碎的大蒜中的生物活性成分是烯丙基硫化合物，被提议通过（i）蛋白S-硫醇化和（ii）产生ROS进行化学反应。 方法 合成了一组R-丙基二硫化物和R-硫代磺酸盐化合物，以探讨硫解和ROS生成在WHCO1食管癌细胞中大蒜相关化合物的细胞毒性中的重要性。 结果  发现细胞毒性IC 50与R-丙基二硫化物和硫代磺酸盐的离去基团pK a之间存在显着的相关性（R 2 = 0.78，Fcrit（7,1）α= 0.005），支持了依赖于C混合二硫化物交换反应。对二硫化物（1）和硫代磺酸盐（11）进行了进一步的机械评估，发现它们可诱导G 2 / M细胞周期停滞和凋亡，抑制细胞增殖并产生ROS。当用Trolox，抗坏血酸或N淬灭1和11产生的ROS时-乙酰半胱氨酸（NAC），只有NAC被发现可以抵消两种化合物的细胞毒性。但是，发现NAC通过混
• Elevated Catalytic Activity of Ruthenium(II)-Porphyrin-Catalyzed Carbene/Nitrene Transfer and Insertion Reactions with N-Heterocyclic Carbene Ligands
  作者：Ka-Ho Chan、Xiangguo Guan、Vanessa Kar-Yan Lo、Chi-Ming Che

  DOI：10.1002/anie.201309888

  日期：2014.3.10

  characterized. Owing to the strong donor strength of axial NHC ligands in stabilizing the trans MCRR′/MNR moiety, these complexes showed unprecedently high catalytic activity towards alkene cyclopropanation, carbene CH, NH, SH, and OH insertion, alkene aziridination, and nitrene CH insertion with turnover frequencies up to 1950 min−1. The use of chiral [Ru(D4‐Por)(BIMe)2] (1 g) as a catalyst led to

  设计，合成和表征了双（NHC）钌（II）-卟啉配合物。由于轴向NHC的强供体强度在稳定配体的反式MCRR'/MNR部分，这些配合物显示出对烯烃环丙烷化unprecedently高的催化活性，卡宾Ç  H，N  H，S  H，和O H插入，烯基叠氮化和亚硝基CH插入，其周转频率高达1950 min -1。手性[Ru（D 4 -Por）（BIMe）2 ]（1 g）的使用导致高对映选择性卡宾/丁二烯转移和插入反应的发生率高达98％ ee。在37°C时可以对肽的N末端进行碳烯修饰。DFT计算表明，反式NHC配体通过稳定金属-卡宾反应中间体来促进重氮化合物的分解。
• NOVEL ANTICANCER CONCOMITANT DRUG
  申请人：CHUGAI SEIYAKU KABUSHIKI KAISHA

  公开号：EP1925309A1

  公开（公告）日：2008-05-28

  A cancer therapeutic agent according to the present invention comprises a combination of compound A described below, or a pharmaceutically acceptable salt thereof, and compound B described below, or a pharmaceutically acceptable salt thereof: Compound A: compound A1 represented by formula (1) below, or water-soluble prodrug A2 thereof; Compound B: at least one type of compound selected from the group consisting of a platinum-type anticancer compound, a gemcitabine-type compound, a 5-FU-type compound, a taxane-type compound, a vinca alkaloid-type compound, an anticancer tyrosine kinase inhibitor compound, and an anticancer monoclonal antibody; (wherein, R11 represents a hydrogen atom, a halogen atom or a C1-C6 alkyl group; R12 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a hydroxyl group; R21 represents a hydrogen atom or a C1-C10 alkyl group which may comprise one to three substituents selected from Group B described below: Group B: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, a di-C1-C6 alkylamino group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the aryl ring may comprise one to three substituents selected from the group consisting of a hydroxy group, a C1-C6 alkoxy group, a halogen atom, an amino group, a mono-C1-C6 alkylamino group, and a di-C1-C6 alkylamino group); and R22 represents a hydrogen atom, an amino group, or a C1-C6 alkyl group that may comprise one to three substituents selected from Group C described below, a C1-C6 alkoxy group that may comprise one to three substituents selected from Group C described below, a C1-C6 alkylthio group that may comprise one to three substituents selected from Group C described below, a mono-C1-C6 alkylamino group that may comprise one to three substituents selected from Group C described below, or a di-C1-C6 alkylamino group that may comprise one to three substituents selected from Group C described below: Group C: a C1-C6 alkoxy group, a hydroxy group, a halogen atom, an amino group, a C3-C7 cycloalkyl group, a heterocycle, and an aryl ring (the aryl ring may comprise one to three substituents selected from the group consisting of a hydroxy group, a C1-C6 alkoxy group, an amino group, a mono-C1-C6 alkylamino group, and a di-C1-C6 alkylamino group).

  根据本发明，一种癌症治疗剂包括以下所述的化合物A的组合物，或其药用可接受的盐，以及以下所述的化合物B的组合物，或其药用可接受的盐：化合物A：以下式（1）表示的化合物A1，或其水溶性前药A2；化合物B：选自铂类抗癌化合物、吉西他滨类化合物、5-氟尿嘧啶类化合物、紫杉醇类化合物、长春碱类化合物、抗癌酪氨酸激酶抑制剂化合物和抗癌单克隆抗体的化合物中的至少一种化合物；（其中，R11代表氢原子、卤原子或C1-C6烷基；R12代表氢原子、卤原子、C1-C6烷基或羟基；R21代表氢原子或C1-C10烷基，可能包括来自下文所述的B组的1至3个取代基：B组：C1-C6烷氧基、羟基、卤原子、氨基、单烷基氨基、双烷基氨基、C3-C7环烷基、杂环和芳基（芳基可能包括来自羟基、C1-C6烷氧基、卤原子、氨基、单烷基氨基和双烷基氨基的1至3个取代基）；R22代表氢原子、氨基或可能包括来自下文所述的C组的1至3个取代基的C1-C6烷基、可能包括来自下文所述的C组的1至3个取代基的C1-C6烷氧基、可能包括来自下文所述的C组的1至3个取代基的C1-C6烷硫基、可能包括来自下文所述的C组的1至3个取代基的单烷基氨基，或可能包括来自下文所述的C组的1至3个取代基的双烷基氨基：C组：C1-C6烷氧基、羟基、卤原子、氨基、C3-C7环烷基、杂环和芳基（芳基可能包括来自羟基、C1-C6烷氧基、氨基、单烷基氨基和双烷基氨基的1至3个取代基）。
• Novel Water-Soluble Prodrugs
  申请人：Umeda Isao

  公开号：US20080015157A1

  公开（公告）日：2008-01-17

  An objective of the present invention is to provide water-soluble prodrugs that can be administered parenterally, and which show excellent water solubility and small interspecies or individual differences and are rapidly converted to the active form by chemical conversion. This invention provides water-soluble prodrugs represented by formula (1), or pharmaceutically acceptable salts, or hydrates or solvates thereof, (wherein, R 1 represents a hydrogen atom, or C1-C6 alkyl group; W represents a divalent group comprising a tertiary amino group or sulfonyl group; and Y represents a residue of a compound represented by Y—OH comprising an alcoholic hydroxyl group).

  本发明的目的是提供可经由肌肉注射给药的水溶性前药，其具有优异的水溶性、小的种间或个体差异，并且可通过化学转化迅速转化为活性形式。本发明提供了由式(1)表示的水溶性前药，或其药学上可接受的盐、水合物或溶剂化物，其中R1代表氢原子或C1-C6烷基；W代表包含三级胺基或磺酰基的二价基团；Y代表由Y-OH表示的化合物的残基，该化合物包括醇羟基。